Overview
Building off prior research on real-world time to next treatment and overall survival among relapsed/refractory patients with Mantle Cell Lymphoma (R/R MCL) who were treated with covalent Bruton's tyrosine kinase inhibitors (cBTKi) including ibrutinib (ibr), acalabrutinib (acala), and zanubrutinib (zanu), this study aimed to further assess treatment patterns, reasons for cBTKi discontinuation and compare effectiveness for patients R/R MCL patients treated with different cBTKi monotherapies.
The results showed that patients treated with zanu had longer overall survival compared to ibr and a trend toward better outcomes over acala. The main reasons for discontinuing treatment were disease progression and toxicity, with toxicity driving many patients to switch from one cBTKi to another. These findings suggest zanu may offer better survival outcomes and lesser toxicity in this patient population.
Why this matters
As oncology treatments continue to evolve, research can leverage real-world data and rigorous methods to provide deeper insights into the real-world patient journey elucidating treatment patterns and potential reasons for differences in patient outcomes. This research improves our understanding of the treatment landscape for patients with R/R MCL while providing clear opportunities for future research to continue improving future treatment strategies.